Direct Answer
Abbott Laboratories is a diversified healthcare company with four segments: medical devices, diagnostics, nutritional products, and established pharmaceuticals. The FreeStyle Libre continuous glucose monitoring system is the highest-growth, highest-margin product line and represents the dominant driver of the long-term investment thesis. The diagnostic segment carries COVID-19 volatility that researchers must strip out to see the underlying Alinity platform trajectory.
Company snapshot
| Field | Detail |
|---|---|
| Company | Abbott Laboratories |
| Ticker | ABT |
| Index | S&P 500, Wilshire 5000 |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Headquarters | Abbott Park, Illinois |
| Founded | 1888 |
| Primary filing source | SEC annual report linked below |
What Abbott Laboratories does
Abbott Laboratories is one of the largest diversified healthcare companies in the world. It operates through four reporting segments that span medical devices, laboratory diagnostics, consumer nutrition products, and branded generic pharmaceuticals sold in developing economies.
The Medical Devices segment is the company's largest by revenue and its fastest-growing. Within that segment, Diabetes Care is the dominant growth engine, anchored by the FreeStyle Libre system, a continuous glucose monitoring (CGM) platform that allows people with diabetes to track blood glucose levels without traditional fingerstick testing. FreeStyle Libre sensors are disposable and worn for 14 days at a time, generating a recurring consumable revenue stream. The Medical Devices segment also includes Cardiac Rhythm Management (pacemakers, defibrillators), Electrophysiology (catheters for heart arrhythmia procedures), Heart Failure (CardioMEMS remote monitoring device), Vascular (stents, vessel closure), and Neuromodulation (spinal cord stimulation, deep brain stimulation).
The Diagnostics segment operates Alinity, a family of laboratory analyzers covering immunoassay, clinical chemistry, hematology and molecular testing. The point-of-care testing portfolio includes the i-STAT system for blood analysis at the bedside and the Panbio line of rapid infectious disease tests. COVID-19 testing drove a large temporary revenue spike in this segment during 2020 through 2022.
Nutritional Products includes well-known consumer brands. Ensure is a line of adult nutritional supplements sold globally through retail. Similac is an infant formula brand, which lost significant U.S. market share following a 2022 manufacturing recall. Pedialyte is a pediatric electrolyte solution. This segment sells through retail pharmacies, grocery stores, and hospitals.
Established Pharmaceuticals (EPD) sells branded generic pharmaceutical products in approximately 130 countries, with the strongest presence in Latin America, India, China, and Africa. These products cover cardiovascular, metabolic, women's health, gastroenterology, and other therapeutic areas.
How Abbott Laboratories makes money
Abbott's four segments generate revenue through different mechanisms, and understanding those mechanisms separately is critical to interpreting financial results.
In Medical Devices, FreeStyle Libre generates revenue primarily from sensor sales. Readers purchase sensors on an ongoing basis, creating a predictable, high-margin consumable revenue stream analogous to a subscription model. Capital equipment and implants in cardiovascular and neuromodulation generate lumpy, procedure-driven revenue. Pricing in medical devices is often negotiated through hospital systems and group purchasing organizations.
In Diagnostics, the Alinity platform uses a reagent-lease model common in laboratory instrumentation. Hospitals install the analyzers at low or no upfront cost, then pay for reagent consumables on a per-test basis. This model creates high switching costs once a hospital's workflow is integrated with Alinity, because transitioning to a competitor's platform requires revalidating hundreds of assays. The COVID testing business operated differently: tests were sold individually at high volume during the pandemic period and then declined sharply as demand normalized.
Nutritional Products revenue is driven by consumer demand for branded nutrition, infant formula and pediatric hydration products. This segment's economics resemble consumer staples: relatively steady demand, brand-dependent pricing, and gross margins that depend on input commodity costs such as dairy and packaging.
Established Pharmaceuticals earns its margin from the brand premium that generic manufacturers command in emerging market countries where regulatory barriers to entry, distribution networks, and physician familiarity create durable competitive positions for branded generics.
Revenue engine
FreeStyle Libre is Abbott's highest-profile growth driver. The CGM market has expanded rapidly as the product has moved beyond insulin-dependent diabetics to the broader population of people managing Type 2 diabetes with oral medications. The global installed base of FreeStyle Libre users measures in the tens of millions. Revenue growth is driven by new user additions, geographic expansion (particularly in emerging markets where reimbursement coverage is expanding), and the transition from earlier Libre 2 and Libre 3 versions to higher-margin premium product lines.
The Alinity platform is a multi-year capital cycle story. Abbott spent heavily to develop and deploy Alinity analyzers, and the installed base generates reagent revenue on an ongoing basis. The unit economics improve over time as the capital cost is amortized and the reagent stream becomes the dominant contribution. Tracking Alinity placements (new instrument installations) is a leading indicator of future reagent revenue growth.
Established Pharmaceuticals revenue is reported in constant currency because the segment operates entirely in non-U.S. markets. Reported results can be significantly distorted by foreign exchange movements, particularly when the dollar strengthens against the currencies of Latin America or India. Investors who rely on reported results without adjusting for currency will misread the underlying business performance.
Business segments
| Segment | Key products | Revenue model | Key metrics |
|---|---|---|---|
| Medical Devices | FreeStyle Libre, CardioMEMS, EP catheters, pacemakers, spinal cord stimulators | Consumable sensors (CGM), device implants, capital equipment | FreeStyle Libre sales growth, procedure volumes |
| Diagnostics | Alinity analyzers, i-STAT, Panbio, COVID tests | Reagent-lease (recurring per-test consumables) | Base diagnostics growth ex-COVID, Alinity placements |
| Nutritional Products | Ensure, Similac, Pedialyte | Branded consumer goods, retail and clinical channels | Market share, pricing, input costs |
| Established Pharmaceuticals | Branded generics, therapeutic areas in EM | Branded generic sales in emerging markets | Constant-currency growth, emerging market mix |
Products, services and customers
FreeStyle Libre is sold directly to patients and through pharmacy channels in over 60 countries. Hospital systems and integrated delivery networks are the primary customer for Alinity diagnostics, i-STAT, and cardiovascular and neuromodulation devices. Retail pharmacy and grocery chains are the primary distribution channel for Ensure, Similac, and Pedialyte. Established Pharmaceuticals sells through local distributor networks in emerging market countries.
The customer base is highly diversified. No single customer accounts for a significant share of total revenue. The mix of hospital systems, retail pharmacy, direct-to-patient consumable sales, and emerging market distributors provides resilience when any individual end market faces pressure.
Geography
Abbott generates roughly half its revenue outside the United States, with the international mix varying by segment. Medical Devices has significant international scale, particularly FreeStyle Libre in Europe, where reimbursement coverage has historically been more extensive than in the U.S. Established Pharmaceuticals is entirely international. Diagnostics operates globally through major hospital systems. Nutritional Products has meaningful revenue in China and other Asian markets alongside its U.S. business.
The international exposure creates currency risk. The company reports both reported and organic (constant-currency) growth rates, and interpreting the organic rate is essential for understanding underlying business performance in periods of significant dollar strength or weakness.
Business-model classification
Abbott operates a blend of recurring consumable revenue, capital equipment deployment, and branded consumer goods. The FreeStyle Libre sensor stream is structurally similar to a subscription in that users replace sensors continuously. The Alinity reagent stream is a classic razor-blade model. Nutritional products are repeat-purchase consumer goods. Established Pharmaceuticals is a branded goods business benefiting from distribution barriers in emerging markets rather than from patent protection.
The result is a company with high revenue visibility and strong free cash flow generation. The combination of consumable sensors, reagent contracts, and branded repeat-purchase nutrition creates a revenue base that does not depend on any single capital equipment decision or patent cliff. Abbott has increased its dividend for more than 50 consecutive years, qualifying it as a Dividend Aristocrat in the S&P 500.
Company economics
Medical Devices generates the highest operating margins in Abbott's portfolio, driven by FreeStyle Libre's consumable economics. Once a user adopts FreeStyle Libre, the ongoing sensor purchases are largely automatic, and Abbott incurs minimal incremental cost to retain that revenue. Gross margins in CGM sensor production are high and improve as manufacturing scale increases.
Diagnostics margins depend heavily on reagent volume relative to the fixed cost of the installed instrument base. The COVID period distorted this analysis significantly. In 2020 and 2021, high-volume COVID testing contributed hundreds of millions in high-margin incremental revenue. As COVID testing demand declined, the segment faced a revenue and margin headwind that had nothing to do with the underlying Alinity business trajectory. Researchers should build a clear picture of base diagnostics growth and margins, separate from COVID-related contributions.
Capital allocation at Abbott follows a consistent framework: fund internal growth through R&D, maintain the dividend growth streak, and use acquisitions selectively to add product capabilities. The company has historically avoided very large transformative acquisitions in favor of bolt-on additions that strengthen existing segments. Return on invested capital has generally been above the company's cost of capital over multi-year periods.
Financial statement guide
Income statement: Revenue is reported by segment. For Medical Devices, track FreeStyle Libre as a line item within the Diabetes Care category, which Abbott discloses separately. For Diagnostics, request or calculate the base business growth by removing COVID-19 testing revenue. Operating margin is the key profitability metric; segment operating income margins differ materially across the four businesses. Net income is affected by goodwill amortization and charges related to acquisitions.
Balance sheet: Abbott carries meaningful long-term debt from historical acquisitions, including the 2017 St. Jude Medical acquisition. Intangible assets and goodwill are large in proportion to total assets, which is normal for a company that has grown partly through acquisition. The company generates strong operating cash flow that comfortably covers interest expense, capital expenditure, and dividends.
Cash flow statement: Operating cash flow is the most important cash flow metric. FreeStyle Libre sensor revenue is cash-generative because it requires limited incremental capital to serve an expanding user base. Capital expenditure is moderate relative to revenue. Free cash flow conversion (free cash flow as a percentage of net income) is typically high.
Segment disclosures: Abbott provides operating income by segment in its quarterly filings. Medical Devices and Diagnostics typically carry the highest absolute operating income. The segment disclosure is the most important starting point for assessing where value is being created and where it is being consumed.
Competitive position
FreeStyle Libre competes primarily with Dexcom in continuous glucose monitoring. Dexcom has historically targeted insulin-dependent patients with physician prescriptions, while Abbott has pursued broader adoption including non-insulin-dependent Type 2 diabetics. The market is large enough to support multiple competitors, and Abbott's lower price point and broad international reimbursement coverage give it access to markets where Dexcom has less penetration.
In diagnostics, Abbott competes with Roche Diagnostics, Siemens Healthineers, and Beckman Coulter. The Alinity platform competes on analyzer throughput, menu breadth, and total cost of operation. Once hospitals have validated their workflow on a platform, switching costs are high, and the competitive dynamic becomes more about winning new installations and renewals than displacing entrenched competitors mid-contract.
Nutritional Products competes with Nestle Health Science (Boost) in adult nutrition and with Reckitt and Danone in infant formula. The Similac brand lost significant U.S. market share following the 2022 recall and has been working to recover it. Ensure's competitive position in the hospital channel and retail pharmacy is supported by long-standing clinical evidence and physician familiarity.
Risks and watchlist
- CGM competitive pressure: Dexcom and new entrants (including Medtronic) compete directly in the CGM segment. Abbott must maintain FreeStyle Libre's price advantage and expand reimbursement to defend its market position.
- Diagnostics COVID normalization: The multi-year decline in COVID test revenue created a persistent headwind in reported diagnostics growth numbers. The risk is that the base business grows more slowly than expected once COVID distortion is fully unwound.
- Infant formula market share recovery: The 2022 Sturgis, Michigan plant contamination and subsequent recall damaged Similac's U.S. brand position substantially. Recovering that share depends on sustained marketing investment and avoiding further quality incidents.
- Currency and emerging market exposure: Established Pharmaceuticals and international Medical Devices are exposed to emerging market currency weakness. A sustained U.S. dollar rally can suppress reported revenue growth even when underlying business performance is solid.
- Regulatory and reimbursement risk: Continuous glucose monitors depend on insurance reimbursement decisions. Coverage expansions drive volume; coverage restrictions or changes in Medicare/Medicaid policy for CGM could affect growth.
- Medical device product liability: Heart device recalls and litigation are recurring risks in the cardiac rhythm management segment. Abbott has faced historical recall-related costs and settlements.
Practical research workflow
Step 1: Read the segment revenue tables. Each quarterly earnings release separates revenue by segment and within Medical Devices by sub-category. Identify FreeStyle Libre revenue specifically, not just Diabetes Care total. Calculate the organic growth rate for base Diagnostics by subtracting any disclosed COVID testing revenue.
Step 2: Analyze segment operating income. The segment operating income disclosure reveals where profitability is concentrated. Compare Medical Devices margins to Diagnostics margins. Track whether FreeStyle Libre's contribution is expanding or compressing.
Step 3: Review FreeStyle Libre metrics. Earnings calls and investor day presentations often provide user count data and geographic mix. Understand the trajectory of new user additions versus sensor revenue per user, because these are the two levers driving the growth rate.
Step 4: Assess the Alinity placement pipeline. New analyzer placements are a leading indicator of future reagent revenue. Abbott occasionally discloses Alinity placement data; investor day materials and sell-side analyst questions at earnings calls are good sources for this figure.
Step 5: Evaluate the dividend and capital return record. Abbott's 50-plus-year dividend growth streak is a key part of the investment proposition for income-oriented investors. Review the payout ratio and free cash flow coverage of the dividend to assess sustainability.
Step 6: Examine primary sources. Abbott's 10-K and 10-Q filings are available through the SEC EDGAR link below. The annual report provides detailed segment disclosures, risk factor descriptions, and geographic revenue breakdowns. Abbott's investor relations website (abbottinvestor.com) provides supplemental financial data, quarterly earnings presentations, and investor day materials.
Frequently asked questions
What does Abbott Laboratories do?
Abbott Laboratories operates four segments: Medical Devices (continuous glucose monitors, heart devices, vascular products), Diagnostics (Alinity laboratory instruments, point-of-care testing), Nutritional Products (Ensure, Similac, Pedialyte) and Established Pharmaceuticals (branded generics sold primarily in emerging markets). Medical Devices is the largest and fastest-growing segment, led by the FreeStyle Libre continuous glucose monitoring platform.
How does Abbott Laboratories make money?
Revenue comes from four segments. Medical Devices generates recurring income from FreeStyle Libre sensor sales (a consumable worn by diabetics on a 14-day replacement cycle) plus capital equipment and implants. Diagnostics uses a reagent-lease model where hospitals install Alinity analyzers and pay for reagent consumables per test. Nutritional Products sells branded consumer goods through retail and clinical channels. Established Pharmaceuticals sells branded generics in roughly 130 countries, primarily in Latin America, India and Africa.
What should investors monitor most closely for Abbott?
FreeStyle Libre sales growth is the single most important organic growth indicator, since it is the highest-margin, fastest-growing product line. Diagnostics should be tracked on a base business basis, excluding COVID-19 testing revenue, to see the underlying trajectory of the Alinity platform. Medical devices operating margin, Established Pharmaceuticals constant-currency growth and any changes to the FreeStyle Libre competitive landscape are also key inputs.
What is the biggest risk when researching Abbott Laboratories?
Conflating total reported diagnostics revenue with the underlying base business trend. COVID-19 testing revenue inflated diagnostics in 2020 through 2022 and then sharply declined, creating a difficult comparison period that masked underlying Alinity growth. Separately, FreeStyle Libre faces direct competition from Dexcom and other CGM makers, and a loss of market share or pricing pressure there would disproportionately affect revenue growth expectations.
Is this page investment advice?
No. It is an educational research framework designed to explain the business and the variables an investor may choose to study.